Fritz H Schroder

Summary

Affiliation: Erasmus MC
Country: The Netherlands

Publications

  1. ncbi Review of diagnostic markers for prostate cancer
    Fritz H Schroder
    Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Recent Results Cancer Res 181:173-82. 2009
  2. doi Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC
    Fritz H Schroder
    Department of Urology, Erasmus MC, University Medical Centre Rotterdam, The Netherlands
    Eur Urol 53:901-8. 2008
  3. doi Early versus delayed endocrine treatment of T2-T3 pN1-3 M0 prostate cancer without local treatment of the primary tumour: final results of European Organisation for the Research and Treatment of Cancer protocol 30846 after 13 years of follow-up (a randomi
    Fritz H Schroder
    Department of Urology, Erasmus MC, Rotterdam, The Netherlands
    Eur Urol 55:14-22. 2009
  4. doi Screening for prostate cancer (PC)--an update on recent findings of the European Randomized Study of Screening for Prostate Cancer (ERSPC)
    Fritz H Schroder
    Department of Urology, Erasmus MC, Rotterdam, The Netherlands
    Urol Oncol 26:533-41. 2008
  5. doi The effect of study arm on prostate cancer treatment in the large screening trial ERSPC
    Tineke Wolters
    Department of Urology, Erasmus MC, Rotterdam, The Netherlands
    Int J Cancer 126:2387-93. 2010
  6. ncbi Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam
    Rene Raaijmakers
    Department of Urology, Erasmus Medical Center, Rotterdam, The Netherlands
    Urology 63:316-20. 2004
  7. doi Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up
    Xiaoye Zhu
    Department of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Eur Urol 60:330-6. 2011
  8. doi A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer
    Monique J Roobol
    Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands
    Eur Urol 57:79-85. 2010
  9. ncbi Potentially advanced malignancies detected by screening for prostate carcinoma after an interval of 4 years
    Renske Postma
    Department of Urology, Erasmus Medical Center, Rotterdam, The Netherlands
    Cancer 100:968-75. 2004
  10. doi Towards an optimal interval for prostate cancer screening
    Pim J van Leeuwen
    Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands
    Eur Urol 61:171-6. 2012

Detail Information

Publications115 found, 100 shown here

  1. ncbi Review of diagnostic markers for prostate cancer
    Fritz H Schroder
    Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Recent Results Cancer Res 181:173-82. 2009
    ..0 ng/ml. The limitations of PSA discussed herein clearly point to the need to find better diagnostic and prognostic markers for prostate cancer...
  2. doi Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC
    Fritz H Schroder
    Department of Urology, Erasmus MC, University Medical Centre Rotterdam, The Netherlands
    Eur Urol 53:901-8. 2008
    ..0 ng/ml were not biopsied (with few exceptions). In the Prostate Cancer Prevention Trial (PCPT) eligible men who initially presented with PSA values <3.0 ng/ml were all biopsied during or at the end of a 7-yr study period...
  3. doi Early versus delayed endocrine treatment of T2-T3 pN1-3 M0 prostate cancer without local treatment of the primary tumour: final results of European Organisation for the Research and Treatment of Cancer protocol 30846 after 13 years of follow-up (a randomi
    Fritz H Schroder
    Department of Urology, Erasmus MC, Rotterdam, The Netherlands
    Eur Urol 55:14-22. 2009
    ..The issue is addressed in European Organisation for the Research and Treatment of Cancer (EORTC) protocol 30846 for patients with lymph node-positive (pN1-3) cancer without local treatment of the primary tumour...
  4. doi Screening for prostate cancer (PC)--an update on recent findings of the European Randomized Study of Screening for Prostate Cancer (ERSPC)
    Fritz H Schroder
    Department of Urology, Erasmus MC, Rotterdam, The Netherlands
    Urol Oncol 26:533-41. 2008
    ..Many pending problems still have to be resolved prior to the introduction of populations based screening as a worldwide healthcare policy...
  5. doi The effect of study arm on prostate cancer treatment in the large screening trial ERSPC
    Tineke Wolters
    Department of Urology, Erasmus MC, Rotterdam, The Netherlands
    Int J Cancer 126:2387-93. 2010
    ..Therefore, differences in treatment between arms are unlikely to play a major role in the interpretation of the results of the ERSPC...
  6. ncbi Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam
    Rene Raaijmakers
    Department of Urology, Erasmus Medical Center, Rotterdam, The Netherlands
    Urology 63:316-20. 2004
    ....
  7. doi Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up
    Xiaoye Zhu
    Department of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Eur Urol 60:330-6. 2011
    ..In a screening program, interval cancers are cancers diagnosed between two screening visits...
  8. doi A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer
    Monique J Roobol
    Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands
    Eur Urol 57:79-85. 2010
    ..Screening for prostate cancer (PC) is controversial due to uncertainties about its efficiency...
  9. ncbi Potentially advanced malignancies detected by screening for prostate carcinoma after an interval of 4 years
    Renske Postma
    Department of Urology, Erasmus Medical Center, Rotterdam, The Netherlands
    Cancer 100:968-75. 2004
    ....
  10. doi Towards an optimal interval for prostate cancer screening
    Pim J van Leeuwen
    Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands
    Eur Urol 61:171-6. 2012
    ..The rate of decrease in advanced cancers is an estimate for determining prostate cancer (PCa) screening program effectiveness...
  11. doi Screening for prostate cancer: results of the Rotterdam section of the European randomized study of screening for prostate cancer
    Monique J Roobol
    Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands
    Eur Urol 64:530-9. 2013
    ..Evidence from randomized trials on the effects of screening for prostate cancer (PCa) on disease-specific mortality accumulates slowly with increasing follow-up...
  12. ncbi Critical assessment of prebiopsy parameters for predicting prostate cancer metastasis and mortality
    Pim J van Leeuwen
    Erasmus University Medical Center, Rotterdam, The Netherlands
    Can J Urol 18:6018-24. 2011
    ..Value of characteristics assessed prior to diagnosis predicting aggressive prostate cancer, metastases and mortality in men participating in a screening study were identified...
  13. doi Screening and prostate-cancer mortality in a randomized European study
    Fritz H Schroder
    Department of Urology, Erasmus Medical Center, Rotterdam, The Netherlands
    N Engl J Med 360:1320-8. 2009
    ..The European Randomized Study of Screening for Prostate Cancer was initiated in the early 1990s to evaluate the effect of screening with prostate-specific-antigen (PSA) testing on death rates from prostate cancer...
  14. ncbi Array-based genomic analysis of screen-detected Gleason score 6 and 7 prostatic adenocarcinomas
    Renske Postma
    Department of Pathology, Erasmus Medical Center, Rotterdam, The Netherlands
    Anticancer Res 26:1193-200. 2006
    ..Prostate cancer is known for its heterogeneous histological appearance. It is currently not clear whether this histological heterogeneity is also reflected in the genomic composition of a tumor...
  15. ncbi Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance
    Stijn Roemeling
    Department of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Eur Urol 50:475-82. 2006
    ..Our knowledge about which prostate cancers are life threatening and which are not is limited. Thus, for ethical, medical, and economic reasons we need to define which patients can be managed by active surveillance...
  16. ncbi Interval carcinomas in the European Randomized Study of Screening for Prostate Cancer (ERSPC)-Rotterdam
    Ingrid W van der Cruijsen-Koeter
    Department of Urology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
    J Natl Cancer Inst 95:1462-6. 2003
    ..We evaluated the time and mechanism of detection and the stage distribution of interval prostate cancers diagnosed during a 4-year screening interval...
  17. ncbi Biochemical progression rates in the screen arm compared to the control arm of the Rotterdam Section of the European Randomized Study of Screening for Prostate Cancer (ERSPC)
    Stijn Roemeling
    Department of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Prostate 66:1076-81. 2006
    ..This report compares the preliminary outcome of cancers detected in the screen and the control arm of its Rotterdam section, by means of biochemical progression rates...
  18. ncbi hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml
    Rene Raaijmakers
    Department of Urology, Erasmus MC, Rotterdam, The Netherlands
    Eur Urol 52:1358-64. 2007
    ..The purpose of this investigation was to evaluate the role of tumour markers total PSA, free PSA, and hK2, and their combinations in predicting minimal prostate cancer...
  19. doi Prostate-cancer mortality at 11 years of follow-up
    Fritz H Schroder
    Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands
    N Engl J Med 366:981-90. 2012
    ..We updated prostate-cancer mortality in the European Randomized Study of Screening for Prostate Cancer with 2 additional years of follow-up...
  20. ncbi Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC)--Section Rotterdam. A comparison of two rounds of screening
    Renske Postma
    Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Eur Urol 52:89-97. 2007
    ..To evaluate the features, rates, and characteristics of prostate cancer detected during two subsequent screening rounds...
  21. doi Effect of the correction for noncompliance and contamination on the estimated reduction of metastatic prostate cancer within a randomized screening trial (ERSPC section Rotterdam)
    Melissa Kerkhof
    Department of Urology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
    Int J Cancer 127:2639-44. 2010
    ..In the population of ERSPC Rotterdam (N = 42,376 men), screening reduces the risk to be diagnosed with metastatic prostate cancer considerably on population level, an effect which is even more pronounced in men who are in fact screened...
  22. ncbi A more advanced clinical stage is positively correlated with an increased prostate cancer detection rate
    Monique J Roobol
    Department of Urology, Dijkzigt Academic Hospital, Rotterdam, The Netherlands
    Urology 59:91-6. 2002
    ..A suspicious digital rectal examination (DRE) and/or a suspicious transrectal ultrasound (TRUS) investigation increases the likelihood of prostate cancer given a certain prostate-specific antigen level...
  23. doi Efficacy versus effectiveness study design within the European screening trial for prostate cancer: consequences for cancer incidence, overall mortality and cancer-specific mortality
    Xiaoye Zhu
    Department of Urology, Erasmus MC, University Medical Center, Room NH 227, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    J Med Screen 19:133-40. 2012
    ..To assess the impact of different study designs on outcome data within the European Randomized Study of Screening for Prostate Cancer (ERSPC)...
  24. doi ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer
    A Marije Hoogland
    Department of Pathology, Erasmus Medical Center, Rotterdam, The Netherlands
    Mod Pathol 25:471-9. 2012
    ..Increasing ERG levels are associated with the upregulation of androgen receptor expression in clinical specimens...
  25. doi The Prostate Cancer Prevention Trial and European Randomized Study of Screening for Prostate Cancer risk calculators indicating a positive prostate biopsy: a comparison
    Roderick C N van den Bergh
    Department of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    BJU Int 102:1068-73. 2008
    ....
  26. doi The value of an additional hypoechoic lesion-directed biopsy core for detecting prostate cancer
    Claartje Gosselaar
    Department of Urology, Erasmus MC, University Medical Centre, Rotterdam, The Netherlands
    BJU Int 101:685-90. 2008
    ..To determine the value of a hypoechoic lesion (HL)-directed biopsy in addition to a systematic sextant biopsy for detecting prostate cancer...
  27. doi Do anxiety and distress increase during active surveillance for low risk prostate cancer?
    Roderick C N van den Bergh
    Erasmus Medical Center, Rotterdam, The Netherlands
    J Urol 183:1786-91. 2010
    ..Anxiety and distress may be present in patients with low risk prostate cancer who are on active surveillance. This may be a reason to discontinue active surveillance...
  28. doi Is delayed radical prostatectomy in men with low-risk screen-detected prostate cancer associated with a higher risk of unfavorable outcomes?
    Roderick C N van den Bergh
    Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands
    Cancer 116:1281-90. 2010
    ..Delay before radical treatment caused by active surveillance may be associated with an impaired chance of curability...
  29. ncbi Gleason score, age and screening: modeling dedifferentiation in prostate cancer
    Gerrit Draisma
    Department of Public Health, Erasmus MC, Rotterdam, The Netherlands
    Int J Cancer 119:2366-71. 2006
    ..Tumors dedifferentiate during the screen-detectable phase and consequently screening with PSA and early treatment can possibly prevent dedifferentiation...
  30. doi Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam)
    Tineke Wolters
    Department of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Eur Urol 55:385-92. 2009
    ..The value of prostate-specific antigen velocity (PSAV) in screening for prostate cancer (PCa) and especially for clinically significant PCa is unclear...
  31. doi Prostate cancer antigen 3: diagnostic outcomes in men presenting with urinary prostate cancer antigen 3 scores ≥100
    Fritz H Schroder
    Department of Urology, Erasmus Medical Center, Rotterdam, The Netherlands Electronic address
    Urology 83:613-6. 2014
    ..To describe the results of 3 rounds of diagnostic testing and linkage to the Dutch Cancer Registry for men with an initial prostate cancer antigen 3 (PCA3) score ≥100...
  32. doi Excess all-cause mortality in the evaluation of a screening trial to account for selective participation
    Ries Kranse
    Department of Urology, Erasmus Medical Centre, Rotterdam, The Netherlands and Comprehensive Cancer Center the Netherlands IKNL, Utrecht, The Netherlands
    J Med Screen 20:39-45. 2013
    ..We studied the effect of not accounting for attendance on the calculated excess mortality in a prostate cancer screening trial...
  33. ncbi 4-year prostate specific antigen progression and diagnosis of prostate cancer in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam
    Fritz H Schroder
    Department of Urology, Erasmus University Rotterdam, The Netherlands
    J Urol 174:489-94; discussion 493-4. 2005
    ..The present study evaluates the predictive value of a prostate specific antigen (PSA) increase to PSA 3.0 ng/ml or greater in a 4-year period in men who present with low PSA values (less than 3.0 ng/ml) at first screen...
  34. doi Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer
    Meelan Bul
    Department of Urology, Erasmus MC, Rotterdam, The Netherlands
    BJU Int 110:1672-7. 2012
    ..Favourable disease-specific outcomes confirm the feasibility of active surveillance for low risk PCa and also support a role for active surveillance in selected patients with intermediate risk PCa...
  35. doi Increased non-prostate cancer death risk in clinically diagnosed prostate cancer
    Pim J van Leeuwen
    Department of Urology Public Health, Erasmus Medical Centre, Rotterdam Cancer Registry Rotterdam, Rotterdam, The Netherlands
    BJU Int 110:188-94. 2012
    ..Men with clinically diagnosed PC have an increased risk of death unrelated to PC itself, i.e., the excess mortality is based on an increased risk of dying from other neoplasm and diseases of the circulatory or respiratory system...
  36. ncbi Feasibility study of adjustment for contamination and non-compliance in a prostate cancer screening trial
    Stijn Roemeling
    Department of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Prostate 67:1053-60. 2007
    ..We present a feasibility study and impact simulation of a secondary analysis, which imitates a situation where all participants in the study are managed according to their random assignment...
  37. ncbi Updating the prostate cancer risk indicator for contemporary biopsy schemes
    Meelan Bul
    Department of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Can J Urol 18:5625-9. 2011
    ..Our objective is to extract correction factors for adjustment of the model, addressing contemporary extended biopsy schemes...
  38. doi Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer
    Johannes Hofland
    Departments of Internal Medicine, Urology, and Pathology, Erasmus MC, P O Box 2040, 3000 CA Rotterdam, The Netherlands
    Cancer Res 70:1256-64. 2010
    ....
  39. ncbi The value of EZH2, p27(kip1), BMI-1 and MIB-1 on biopsy specimens with low-risk prostate cancer in selecting men with significant prostate cancer at prostatectomy
    Tineke Wolters
    Department of Urology, Erasmus Medical Center, Rotterdam, The Netherlands
    BJU Int 106:280-6. 2010
    ....
  40. ncbi Metastatic disease of screen-detected prostate cancer : characteristics at diagnosis
    Stijn Roemeling
    Department of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Cancer 107:2779-85. 2006
    ..Risk stratification of screen-detected cancers at diagnosis has become more important for the anticipation and interpretation of changing incidence/mortality ratios...
  41. doi Prostate cancer incidence and disease-specific survival of men with initial prostate-specific antigen less than 3.0 ng/ml who are participating in ERSPC Rotterdam
    Meelan Bul
    Department of Urology, Erasmus MC, University Medical Centre, Rotterdam, The Netherlands
    Eur Urol 59:498-505. 2011
    ..The European Randomised Study of Screening for Prostate Cancer (ERSPC) applies a prostate-specific antigen (PSA) cut-off value ≥3.0 ng/ml as an indication for lateralised sextant biopsy...
  42. ncbi Can non-malignant biopsy features identify men at increased risk of biopsy-detectable prostate cancer at re-screening after 4 years?
    Tineke Wolters
    Department of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    BJU Int 101:283-8. 2008
    ..To identify pathological features in non-malignant sextant prostate needle biopsies and assess their predictive value for detecting prostate cancer on biopsy 4 years later...
  43. ncbi Impacts of a population-based prostate cancer screening programme on excess total mortality rates in men with prostate cancer: a randomized controlled trial
    Pim J van Leeuwen
    Erasmus University MedicalCentre, Rotterdam, The Netherlands
    J Med Screen 20:33-8. 2013
    ..To assess the effect of screening in terms of excess mortality in the European Randomized Study of Screening for Prostate Cancer (ERSPC)...
  44. ncbi Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC)
    Fritz H Schroder
    Erasmus MC, Rotterdam, The Netherlands
    Can J Urol 12:2-6; discussion 92-3. 2005
    ....
  45. ncbi Evaluation of genetic patterns in different tumor areas of intermediate-grade prostatic adenocarcinomas by high-resolution genomic array analysis
    Herman van Dekken
    Department of Pathology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
    Genes Chromosomes Cancer 39:249-56. 2004
    ..The patterns of imbalance could be found to coincide in the G3 and G4 areas of the majority of cancers. Array-based CGH can be used as a tool for the evaluation of genetic patterns in prostate cancer...
  46. ncbi Comparison of screen detected and clinically diagnosed prostate cancer in the European randomized study of screening for prostate cancer, section rotterdam
    Ingrid W van der Cruijsen-Koeter
    Departments of Urology, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands
    J Urol 174:121-5. 2005
    ..This report provides a comparison of characteristics detected in the screening and control arms of the European Randomized study of Screening for Prostate Cancer, section Rotterdam...
  47. doi Active surveillance for low-risk prostate cancer
    Chris H Bangma
    Department of Urology, Erasmus MC, Rotterdam, The Netherlands
    Crit Rev Oncol Hematol 85:295-302. 2013
    ....
  48. doi Positive predictive value of prostate biopsy indicated by prostate-specific-antigen-based prostate cancer screening: trends over time in a European randomized trial*
    Leonard P Bokhorst
    Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands
    BJU Int 110:1654-60. 2012
    ..In men who have previously had a benign biopsy, the PPV drops considerably, but 20% of the cancers detected still show aggressive characteristics...
  49. doi Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC)
    Fritz H Schroder
    Department of Urology, Erasmus MC, Rotterdam, The Netherlands
    Eur Urol 62:745-52. 2012
    ..Metastatic disease is a major morbidity of prostate cancer (PCa). Its prevention is an important goal...
  50. doi Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators
    Monique J Roobol
    Erasmus University Medical Centre, Department of Urology, Rotterdam, The Netherlands
    Eur Urol 61:577-83. 2012
    ..The European Randomized Study of Screening for Prostate Cancer (ERSPC) risk calculators (RCs) are validated tools for prostate cancer (PCa) risk assessment and include prostate volume (PV) data from transrectal ultrasound (TRUS)...
  51. doi Performance of prostate cancer antigen 3 (PCA3) and prostate-specific antigen in Prescreened men: reproducibility and detection characteristics for prostate cancer patients with high PCA3 scores (≥ 100)
    Monique J Roobol
    Erasmus Medical Center, University Medical Center, Rotterdam, The Netherlands
    Eur Urol 58:893-9. 2010
    ..Therefore a high PCA3 score should result in a high positive predictive value (PPV) and specificity for a positive biopsy...
  52. ncbi Overall and disease-specific survival of patients with screen-detected prostate cancer in the European randomized study of screening for prostate cancer, section Rotterdam
    Stijn H de Vries
    Department of Urology, Erasmus MC, Rotterdam, The Netherlands
    Eur Urol 51:366-74; discussion 374. 2007
    ....
  53. ncbi Does PSA velocity predict prostate cancer in pre-screened populations?
    Fritz H Schroder
    Department of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Eur Urol 49:460-5; discussion 465. 2006
    ..An elevated PSA in secondary screens may indicate benign enlargement of the prostate rather than prostate cancer. In such cases the yearly rate of increase of PSA (PSA velocity [PSAV]) may improve the test characteristics of PSA...
  54. doi Prediction of prostate cancer in unscreened men: external validation of a risk calculator
    Heidi A van Vugt
    Department of Urology, Erasmus Medical Center, Rotterdam, The Netherlands
    Eur J Cancer 47:903-9. 2011
    ..Prediction models need external validation to assess their value beyond the setting where the model was derived from...
  55. ncbi Risk of cardiovascular mortality in prostate cancer patients in the Rotterdam randomized screening trial
    Suzie J Otto
    Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
    J Clin Oncol 24:4184-9. 2006
    ....
  56. doi Should pathologists routinely report prostate tumour volume? The prognostic value of tumour volume in prostate cancer
    Tineke Wolters
    Department of Pathology, Erasmus MC, Rotterdam, The Netherlands Department of Urology, Erasmus MC, Rotterdam, The Netherlands
    Eur Urol 57:821-9. 2010
    ..In addition, tumour volume might be of value in substaging of pathologic tumour stage (pT2) prostate cancer (PCa)...
  57. ncbi Randomized, double-blind, placebo-controlled crossover study in men with prostate cancer and rising PSA: effectiveness of a dietary supplement
    Fritz H Schroder
    Department of Urology, Erasmus MC Rotterdam, The Netherlands
    Eur Urol 48:922-30; discussion 930-1. 2005
    ..The present tertiary prevention study reports on the effect of a dietary supplement in comparison with placebo on the rate of increase of prostate-specific antigen (PSA)...
  58. ncbi Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the "European Organization for Research and Treatment of Cancer" (EORTC) Protocol 30892
    Fritz H Schroder
    Department of Urology, Erasmus MC, P O Box 2040 3000 CA Rotterdam, The Netherlands
    Eur Urol 45:457-64. 2004
    ..The results pertaining to sexual function were already reported [Br J Cancer 82(2) (2000) 283]...
  59. ncbi Side-effects of treatment for localized prostate cancer: are they valued differently by patients and healthy controls?
    Ida J Korfage
    Department of Public Health, Erasmus MC, University Medical Centre, Rotterdam, The Netherlands
    BJU Int 99:801-6. 2007
    ....
  60. ncbi Dietary intervention in prostate cancer patients: PSA response in a randomized double-blind placebo-controlled study
    Ries Kranse
    Department of Urology, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands
    Int J Cancer 113:835-40. 2005
    ..If future studies confirm that these observations translate into a slowing of disease progression, a dietary intervention may become an attractive option for prostate cancer treatment and prevention...
  61. doi Risk-based prostate cancer screening
    Xiaoye Zhu
    Department of Urology, Erasmus MC University Medical Center, Rotterdam, The Netherlands
    Eur Urol 61:652-61. 2012
    ..Therefore, patient stratification with regard to PCa risk and aggressiveness is necessary to identify those men who are at risk and may actually benefit from early detection...
  62. doi Eleven-year outcome of patients with prostate cancers diagnosed during screening after initial negative sextant biopsies
    Fritz H Schroder
    Department of Urology, Erasmus MC, University Medical Center, P O Box 2040, 3000 CA Rotterdam, The Netherlands
    Eur Urol 57:256-66. 2010
    ..The appropriate way of biopsying a prostate remains controversial. Is sextant biopsy still adequate with repeat screening?..
  63. doi False-negative prostate needle biopsies: frequency, histopathologic features, and follow-up
    Tineke Wolters
    Department of Pathology, Erasmus Medical Center, Rotterdam, The Netherlands
    Am J Surg Pathol 34:35-43. 2010
    ....
  64. doi Comparison of incidentally detected prostate cancer with screen-detected prostate cancer treated by prostatectomy
    Tineke Wolters
    Department of Urology, Erasmus MC Rotterdam, The Netherlands
    Prostate 72:108-15. 2012
    ..Objective of this study is to compare PC detected by PSA screening at subsequent screening rounds and treated by radical prostatectomy (RP) with PC incidentally found in cystoprostatectomy specimens...
  65. doi Anxiety and distress during active surveillance for early prostate cancer
    Roderick C N van den Bergh
    Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands
    Cancer 115:3868-78. 2009
    ..In this study, these feelings were quantified, and their associations with various psychologic, medical, demographic, and decision-related factors were assessed...
  66. ncbi Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer
    Gerrit Draisma
    Department of Public Health, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    J Natl Cancer Inst 95:868-78. 2003
    ..Both consequences have considerable impact on the net benefits of screening...
  67. ncbi Prevalence, treatment modalities and prognosis of familial prostate cancer in a screened population
    Stijn Roemeling
    Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands
    J Urol 175:1332-6. 2006
    ..The clinical presentation and prognosis of familial disease remain uncertain. In this study these entities are evaluated in the first and second rounds of a screening program in The Netherlands...
  68. doi Does "normal" aging imply urinary, bowel, and erectile dysfunction? A general population survey
    Ida J Korfage
    Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
    Urology 72:3-9. 2008
    ..We assessed if urinary, bowel, and sexual dysfunction and associated bother were part of the "normal" aging process in the general male Dutch population...
  69. doi Prostate-specific antigen kinetics in clinical decision-making during active surveillance for early prostate cancer--a review
    Roderick C N van den Bergh
    Department of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Eur Urol 54:505-16. 2008
    ..The kinetics of prostate specific antigen (PSA) are generally assumed to be indicative of tumour progression and are therefore used in clinical decision-making in men on active surveillance for early prostate cancer...
  70. ncbi Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics, PSA doubling times, and outcome
    Stijn Roemeling
    Department of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Eur Urol 51:1244-50; discussion 1251. 2007
    ..To study active surveillance as a management option for the important number of prostate cancer patients who would not have been diagnosed in the absence of screening...
  71. ncbi Screening for prostate cancer at low PSA range: the impact of digital rectal examination on tumor incidence and tumor characteristics
    Claartje Gosselaar
    Department of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Prostate 67:154-61. 2007
    ..To compare tumor characteristics of screen-detected prostate cancers (PCs) either by digital rectal examination (DRE) or by prostate-specific antigen (PSA) as biopsy indication at low PSA...
  72. ncbi Overall survival in the intervention arm of a randomized controlled screening trial for prostate cancer compared with a clinically diagnosed cohort
    Andre N Vis
    Department of Urology, Erasmus Medical Center, Rotterdam, The Netherlands
    Eur Urol 53:91-8. 2008
    ..Overall survival in both cohorts was compared with that in the general population...
  73. ncbi Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam
    Monique J Roobol
    Department of Urology, Erasmus Medical Centre, Rm NH 224, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    J Natl Cancer Inst 99:1296-303. 2007
    ..Variations in the screening algorithm, such as the interval between screening rounds, likely influence the morbidity, mortality, and quality of life of the screened population...
  74. doi Gleason score 7 screen-detected prostate cancers initially managed expectantly: outcomes in 50 men
    Roderick C N van den Bergh
    Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands
    BJU Int 103:1472-7. 2009
    ..CONCLUSION In selected patients with screen-detected Gleason 3 + 4 = 7 prostate cancer, AS might be an option, especially in those with comorbidity and/or a short life-expectancy...
  75. ncbi Early detection of prostate cancer in 2007. Part 1: PSA and PSA kinetics
    Fritz H Schroder
    Department of Urology, Erasmus MC, Rotterdam, The Netherlands
    Eur Urol 53:468-77. 2008
    ..Screening for PCa has not yet been shown to lower PCa mortality. Still, opportunistic screening is wide spread in Europe and in most other parts of the world...
  76. doi Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly
    Roderick C N van den Bergh
    Department of Urology, Erasmus University Medical Centre, Rotterdam, The Netherlands
    Eur Urol 55:1-8. 2009
    ..Many of these cancers will not progress, and radical therapy may lead to substantial overtreatment. Active surveillance (AS) has emerged as an alternative...
  77. ncbi The actual value of the surgical margin status as a predictor of disease progression in men with early prostate cancer
    Andre N Vis
    Department of Urology, Erasmus Medical Center, Rotterdam, The Netherlands
    Eur Urol 50:258-65. 2006
    ..In this study, a critical analysis of the predictive value of the surgical margin status was performed...
  78. doi Identifying and characterizing "escapes"-men who develop metastases or die from prostate cancer despite screening (ERSPC, section Rotterdam)
    Xiaoye Zhu
    Department of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Int J Cancer 129:2847-54. 2011
    ..Subsequently, we can achieve improvements of the current screening algorithm, which hopefully will further decrease PCa-specific mortality without increasing overdiagnosis and overtreatment...
  79. doi The role of the digital rectal examination in subsequent screening visits in the European randomized study of screening for prostate cancer (ERSPC), Rotterdam
    Claartje Gosselaar
    Department of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Eur Urol 54:581-8. 2008
    ..The value of digital rectal examination (DRE) as a screening test for prostate cancer (PC) is controversial in the current prostate-specific antigen (PSA) era...
  80. doi Defining increased future risk for prostate cancer: evidence from a population based screening cohort
    Fritz H Schroder
    Department of Urology, Erasmus MC, University Medical Centre, Rotterdam, The Netherlands
    J Urol 181:69-74; discussion 74. 2009
    ..We examined the population risk during 4 years, defined a prostate specific antigen associated with this risk and clarified the contribution of other predictive factors...
  81. doi Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC)
    Monique J Roobol
    Department of Urology, Erasmus MC, University Medical Centre, Rotterdam, The Netherlands
    Eur Urol 56:584-91. 2009
    ..This effect may be diluted by nonattendance in men randomised to the screening arm and contamination in men randomised to the control arm...
  82. ncbi Effective PSA contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer
    Suzie J Otto
    Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
    Int J Cancer 105:394-9. 2003
    ..Although the reasons for ordering PSA test or indicating biopsy are unknown, effective PSA contamination in the Rotterdam ERSPC section is low and not likely to jeopardize the power of the trial...
  83. doi Expression of the androgen-regulated fusion gene TMPRSS2-ERG does not predict response to endocrine treatment in hormone-naïve, node-positive prostate cancer
    Joost L Boormans
    Department of Urology, Erasmus Medical Centre Rotterdam, Rotterdam, The Netherlands
    Eur Urol 57:830-5. 2010
    ....
  84. ncbi Should we replace the Gleason score with the amount of high-grade prostate cancer?
    Andre N Vis
    Department of Urology, Erasmus Medical Center, Rotterdam, The Netherlands
    Eur Urol 51:931-9. 2007
    ..We investigated the predictive value of the amount of high-grade cancer (Gleason growth patterns 4/5) in the biopsy for prostate-specific antigen (PSA) and clinical relapse after radical prostatectomy...
  85. doi Erectile dysfunction and mental health in a general population of older men
    Ida J Korfage
    Department of Public Health, Erasmus Medical Center, University Medical Center, Rotterdam, The Netherlands
    J Sex Med 6:505-12. 2009
    ..Erectile dysfunction (ED) is more prevalent with increasing age. Previous studies showed that ED was negatively associated with mental health (MH) in specific patient groups...
  86. ncbi Prevalence and characteristics of screen-detected prostate carcinomas at low prostate-specific antigen levels: aggressive or insignificant?
    Claartje Gosselaar
    Department of Urology Screening unit for prostate cancer, Erasmus University, Rotterdam, The Netherlands
    BJU Int 95:231-7. 2005
    ..The favourable characteristics of tumours detectable at very low PSA levels seem to justify the conclusion that an unknown but sizeable proportion of the cancers found at biopsy are clinically insignificant...
  87. ncbi Nomogram use for the prediction of indolent prostate cancer: impact on screen-detected populations
    Stijn Roemeling
    Department of Urology, Erasmus MC, University Medical Center, Rotterdam, Netherlands
    Cancer 110:2218-21. 2007
    ..Not all cancers deserve immediate treatment. It has therefore become more important to be able to identify those cases of screen-detected prostate cancer most likely to show indolent behavior...
  88. ncbi Incidence and follow-up of patients with focal prostate carcinoma in 2 screening rounds after an interval of 4 years
    Rensbe Postma
    Department of Urology, Erasmus Medical Center, Rotterdam, The Netherlands
    Cancer 103:708-16. 2005
    ....
  89. ncbi Prostate cancer diagnosis: the impact on patients' mental health
    Ida J Korfage
    Department of Public Health, Erasmus MC, University Medical Center Rotterdam, P O Box 1738, 3000 DR Rotterdam, The Netherlands
    Eur J Cancer 42:165-70. 2006
    ..The methodological implication is that considering a post-diagnosis assessment as 'baseline' may lead to an underestimation of the patient's mental health...
  90. doi Can dutasteride delay or prevent the progression of prostate cancer in patients with biochemical failure after radical therapy? Rationale and design of the Avodart after Radical Therapy for Prostate Cancer Study
    Fritz H Schroder
    Erasmus MC, Rotterdam, The Netherlands
    BJU Int 103:590-6. 2009
    ....
  91. ncbi A comparison of first and repeat (four years later) prostate cancer screening in a randomized cohort of a symptomatic men aged 55-75 years using a biopsy indication of 3.0 ng/ml (results of ERSPC, Rotterdam)
    Monique J Roobol
    Department of Urology, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands
    Prostate 66:604-12. 2006
    ..The identification of predictors for prostate biopsy outcome at two screening rounds using a PSA>or=3.0 ng/ml as biopsy indication...
  92. doi Disease insight and treatment perception of men on active surveillance for early prostate cancer
    Roderick C N van den Bergh
    Department of Urology, Erasmus Medical Center, Rotterdam, The Netherlands
    BJU Int 105:322-8. 2010
    ..Survey (prospective cohort)...
  93. doi Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways
    Andre N Vis
    Department of Urology, VU Medical Centre, Amsterdam, The Netherlands
    BJU Int 104:438-48. 2009
    ..The objective of this review is to provide an understanding of the mechanisms that prostate cancer cells use to bypass androgen-deprived conditions...
  94. doi Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit
    Pim J van Leeuwen
    Erasmus University Medical Centre, Rotterdam, The Netherlands
    Eur J Cancer 46:377-83. 2010
    ..To estimate the benefits of prostate-specific antigen (PSA) screening on prostate cancer (Pca) metastasis and Pca-specific mortality, we compared two populations with a well-defined difference in intensity of screening...
  95. doi Short-term outcomes of the prospective multicentre 'Prostate Cancer Research International: Active Surveillance' study
    Roderick C N van den Bergh
    Department of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    BJU Int 105:956-62. 2010
    ....
  96. ncbi Detection rates of high-grade prostate cancer during subsequent screening visits. Results of the European Randomized Screening Study for Prostate Cancer
    Theodorus H van der Kwast
    Department of Pathology and Urology, Erasmus Medical Center, Rotterdam, The Netherlands, and Centro per la Studio e la Prevenzione Oncologica, University of Florence, Italy
    Int J Cancer 118:2538-42. 2006
    ..e. 507/10,000 men). Variations in detection rates among screening centers related among others to biopsy compliance and age range...
  97. ncbi Key targets of hormonal treatment of prostate cancer. Part 2: the androgen receptor and 5alpha-reductase
    Andre N Vis
    Department of Urology, VU Medical Centre, Amsterdam, The Netherlands
    BJU Int 104:1191-7. 2009
    ..The objective of this review is to provide an understanding of the pharmacological properties and the potential clinical benefits of 5AR inhibition...
  98. doi Prostate cancer around the world. An overview
    Fritz H Schroder
    Department of Urology, Erasmus Medical Centre, Rotterdam, The Netherlands
    Urol Oncol 28:663-7. 2010
    ..The possibility of early detection of prostate cancer is attractive to clinicians and potential patients in spite of the fact that until recently concrete evidence that screening would influence prostate cancer mortality was lacking...
  99. ncbi Digital rectal examination is no longer necessary in the routine follow-up of men with undetectable prostate specific antigen after radical prostatectomy: the implications for follow-up
    Brian John Chaplin
    Department of Urology, CA Rotterdam, Netherlands
    Eur Urol 48:906-10. 2005
    ..We discuss the implications of our findings...
  100. ncbi Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study
    Fritz H Schroder
    Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands
    BJU Int 106:182-7. 2010
    ..This suggests that degarelix might offer better S-ALP control than leuprolide and might prolong control of skeletal metastases, compared with GnRH agonists, over a 1-year treatment period...
  101. doi Defining the optimal prostate-specific antigen threshold for the diagnosis of prostate cancer
    Fritz H Schroder
    Department of Urology, Erasmus MC, University Medical Centre, Rotterdam, The Netherlands
    Curr Opin Urol 19:227-31. 2009
    ..There is uncertainty about its proper use in diagnosing prostate cancer. This review describes the background of the addressed problem and summarizes relevant, recent findings reported during 2008...